Metformin Monotherapy Significantly Improves Anthropometric and Glycemic Values in Overweight Type 2 Diabetes Mellitus: One Year or More Prospective Study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 102
- 试验地点
- 2
- 主要终点
- Change in Weight From Baseline at 12 Months or More
研究概览
简要总结
The study included 102 overweight type 2 diabetes mellitus patients with a body mass index (BMI) of more than 25 in an open label study. They were advised intensive life style modification which was reinforced at each follow-up visit. In addition they were prescribed extended release metformin (XR) in a gradually increasing tolerable dose, starting with 0.5g twice a day after meals. In addition, hypertension and dyslipidemia, when present, were treated with appropriate recommended drugs. Those who completed a satisfactory regular follow-up for at least 12 months or more were then analyzed for changes in their anthropometric measurements and glycemic control.
详细描述
From 1st February 2006 till 31st December 2008, 800 cases of diabetes mellitus who attended the diabetes clinic constituted the subjects for the present study. Majority of the subjects were from the state of Uttar Pradesh (UP). UP is the fifth largest state of India, Lucknow being the capital of UP. The area of UP is 238,566 Km². Population of UP as per census of 2001 was 166,197,921 (Census of India, www.censusindia.net). Informed written consent, printed and read out in the local language (Hindi), as per GCP guidelines (www.fda.gov./oc/gcp) was obtained from every participant of the study. The study protocol was approved by a duly constituted human ethics committee prior to start of the study.
Height was measured with a calibrated height measuring scale to the nearest cm. Subjects were requested to stand upright without shoes with their back against the scale, heels together and eyes directed forward. Weight was measured with a digital balance (Camry®). The scale was checked every day and calibration was done with "known" weights. Subjects were asked to wear minimum clothing and weight was recorded to the nearest 0.5 kg. Body mass index (BMI) was calculated using the formula: weight (kg)/height (m2). Waist was measured using a non-stretchable measuring tape without any clothing. Waist girth was measured at the midpoint point between the lowest point of the costal margin and the highest point of iliac crest in the midaxillary line at minimal respiration. Hip girth was measured as the greatest circumference at the level of greater trochanters with minimal thin clothing. Measurements were made to the nearest centimeter. Waist and hip ratio (WHR) was calculated by dividing the waist circumference (cm) with the hip circumference (cm). Blood pressure was recorded in the sitting position in the right arm to the nearest 1mm of Hg using a mercury sphygmomanometer, calibrated at least once a week. Two readings were taken at 5 minutes apart and the mean of the two was taken as the blood pressure. Fundus examination with dilated pupils by an ophthalmologist was done in all patients at the beginning of the study.
Diabetes was diagnosed as per American Diabetes Association (ADA) guidelines, based either on the past medical records or present blood glucose values which showed unequivocal raised fasting blood glucose of more than > 116mg% and post-prandial or post-glucose values of > 200mg%. No case of IGT or IFG was included in the study. Current age was defined as the age at the time of examination (2006 - 2008). Duration of diabetes was taken as the difference between the current date and the date when the fasting or post-prandial blood sugar level met the ADA diabetes diagnostic criteria.
The study participants had direct consultation sessions with the study nutritionist, at the beginning of the study and at every monthly follow-up visits. A standard diet according to the ADA guidelines was advised, with 500-1000 kcal/day less (depending on the patient's starting weight and acceptance) than the individual patient's requirement. Special emphasis was placed on avoiding fried food, increasing intake of monounsaturated fats, low fat milk, fibers, vegetables and fruits. Fruits and milk are often avoided by our patients due to the misconception that fruits, except one apple a day, are harmful in diabetes and that milk is "fattening". The patients were also encouraged to take non-cereal diet consisting of low fat milk or yoghurt, fruits, vegetables and green salads, once a week. Each individual was given and explained a detailed individualized diet sheet (in the local language) first by the dietitian and then by the authors. They were asked to undertake some form of aerobic exercise, at least brisk walking (5 kilometers/hour) for 45 minutes daily, or at least 5 days a week. Where available and affordable, they were encouraged to join a health-club/gymnasium where they could do graded aerobic and resistance exercises under supervision. All patients were advised to quit tobacco use in any form. None of our study subjects were in the habit of taking alcohol regularly. Those, who took alcohol, never consumed more than 100ml of spirit per week. Nonnutritive sweeteners were allowed in moderation within the limits of recommendations of ADA. On each subsequent visit, the importance of diet and exercise were re-emphasized by the dietitian, paraclinical staff and the authors. Each case was interviewed in detail about the diet and exercise regimen they were following and corrections, if any, were suggested. Each patient was supplied with printed material in local language about diabetes in general and diet in particular. Drug treatment for hypertension and hyperlipidemia, wherever indicated, were not withheld during the study period.
The extended release metformin (XR), used in the present study was Bigsens XR® (Zydus CND), comprising a dual hydrophilic polymer matrix system. The starting dose of metformin (XR) was 0.5g twice daily after meal; the dose was gradually increased to the maximal tolerated dose. Those patients who were on some other anti-diabetic drug therapy; a 4 weeks washout period was given. All the subjects were informed that at the beginning of the study there was a possibility of initial increase in their blood glucose values, but the same would settle down as they adhere to our lifestyle protocol and as the dose of metformin is increased on subsequent visits. They were also informed about the possible passage of "ghost tablet" in their stool. Patients were told to withhold metformin for at least 5 days prior to any iodinated contrast radiographic study. Every patient was asked to perform urine dip stick test for acetone, at least every week and if found positive to contact this clinic immediately. They were also asked to report immediately in case of developing dyspnoea, marked vomiting, lethargy or fatigue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 Diabetes Mellitus
- •BMI more than 25
排除标准
- •Type 1 diabetes
- •pancreatic diabetes
- •presence of concomitant endocrinal disorder
- •non-overweight type 2 diabetes
- •type 2 diabetes with secondary failure to sulfonylurea and taking insulin
- •presence of proliferative retinopathy or chronic renal failure
- •known cirrhosis of liver
- •heavy alcoholic
- •presence of active tuberculosis
- •known HIV disease or any active infection
- •major mental illness
- •failure to comply with the exercise advice due to physical incapacity (e.g., severe osteoarthritis, hemiparesis or any other disabling neurological disease)
- •present pregnancy (or planning pregnancy)
- •lactating mothers
- •using any kind of hormones including oral contraceptives, systemic corticosteroids, nicotinic acid
- •use of anti-obesity drug within the past 3 months
- •chronic gastroparesis or chronic severe gastrointestinal symptoms
- •a history of gastric or duodenal ulcers
- •abdominal surgery within 1 year will not be included in the study
- •patients with congestive heart failure or overt nephropathy will also not be included, due to unreliability of anthropometric measurements in such subjects and the relative risk of lactic acidosis
结局指标
主要结局
Change in Weight From Baseline at 12 Months or More
时间窗: Initial and at the end of 12 months or more
Change: Weight after 12 months of therapy or more - weight at baseline
Change in Body Mass Index (BMI) From Baseline at 12 Months or More
时间窗: Initial and at the end of 12 months or more
Change: Body Mass Index (BMI) after 12 months of therapy or more - BMI at baseline
Change in Waist Circumference From Baseline at 12 Months or More
时间窗: Initial and at the end of 12 months or more
Change: Waist circumference after 12 months or more of therapy - Waist circumference at baseline
Change in Waist Circumference (Cms)/Hip Circumference (Cms)From Baseline at 12 Months or More
时间窗: Initial and at the end of 12 months or more
Change: Waist circumference/Hip circumference ratio after 12 months or more of therapy - Waist circumference/Hip circumference ratio at baseline
Change in Waist (Cms) /Height (Meters) Ratio From Baseline at 12 Months or More
时间窗: Initial and at the end of 12 months or more
Change: Waist/Height ratio after 12 months or more of therapy - Waist/Height ratio at baseline
Change in Fasting Blood Glucose From Baseline at 12 Months or More
时间窗: Initial and at the end of 12 months or more
Change: Fasting blood glucose after 12 months or more of therapy - Fasting blood glucose at baseline
Change in Glycosylated Haemoglobin (A1C) From Baseline at 12 Months or More
时间窗: Initial and at the end of 12 months or more
Change: Glycosylated Haemoglobin after 12 months or more of therapy - Glycosylated Haemoglobin at baseline.
次要结局
未报告次要终点
